Poseida Therapeutics, Inc. (PSTX) |
|
7.35 0.03 (0.41%)
|
01-27 16:00 |
|
Open: |
7.32 |
Pre. Close: |
7.32 |
|
High:
|
7.47 |
Low:
|
7.16 |
|
Volume:
|
268,019 |
Market Cap:
|
632(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:47:17 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 8.92 One year: 10.42 |
| Support: |
Support1: 5.9  Support2: 4.82 |
| Resistance: |
Resistance1: 7.63 Resistance2: 8.92 |
| Pivot: |
7.01 |
| Moving Average: |
MA(5): 7.34 MA(20): 6.74
MA(100): 4.77 MA(250): 3.85 |
| MACD: |
MACD(12,26): 0.5 Signal(9): 0.5 |
| Stochastic oscillator: |
%K(14,3): 78.1 %D(3): 82.1 |
| RSI: |
RSI(14): 64.6 |
| 52-week: |
High: 7.63 Low: 1.82 |
| Average Vol(K): |
3-Month: 506 (K) 10-Days: 347 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PSTX ] has closed below upper band by 27.4%. Bollinger Bands are 3.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.48 - 7.51 |
7.51 - 7.54 |
|
Low:
|
7.09 - 7.12 |
7.12 - 7.15 |
|
Close:
|
7.3 - 7.35 |
7.35 - 7.4 |
|
Company Description |
|
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California. |
Headline News |
Fri, 27 Jan 2023
Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Fri, 27 Jan 2023
Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the ... - Nasdaq
Wed, 25 Jan 2023
Is Poseida Therapeutics Inc (PSTX) a Winner in the Biotechnology Industry? - InvestorsObserver
Sat, 21 Jan 2023
Poseida Therapeutics Inc. (NASDAQ: PSTX)'s 8.72% Gain This ... - Marketing Sentinel
Thu, 19 Jan 2023
12 Biotech Stocks Hit New Highs; Did You Make The Most Of It? - Nasdaq
Tue, 10 Jan 2023
Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
86 (M) |
| Shares Float |
53 (M) |
|
% Held by Insiders
|
29.7 (%) |
|
% Held by Institutions
|
50.3 (%) |
|
Shares Short
|
2,490 (K) |
|
Shares Short P.Month
|
2,190 (K) |
Stock Financials |
|
EPS
|
-2.32 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.51 |
|
Profit Margin (%)
|
-19.3 |
|
Operating Margin (%)
|
-29.2 |
|
Return on Assets (ttm)
|
-8.7 |
|
Return on Equity (ttm)
|
-16 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.36 |
|
Sales Per Share
|
1.76 |
|
EBITDA (p.s.)
|
-0.46 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-21 (M) |
|
Levered Free Cash Flow
|
-34 (M) |
Stock Valuations |
|
PE Ratio
|
-3.17 |
|
PEG Ratio
|
-5.2 |
|
Price to Book value
|
2.91 |
|
Price to Sales
|
4.16 |
|
Price to Cash Flow
|
-30.52 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
